Clinical Trial Results Week by Week
Tirzepatide (Mounjaro/Zepbound) produces the largest weight loss of any approved medication in clinical trials — averaging 22.5% of body weight over 72 weeks in the SURMOUNT-1 trial at the highest dose.
The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight and at least one weight-related condition. Participants received tirzepatide or placebo for 72 weeks. The results established tirzepatide as the most effective approved obesity medication in history.
Source: SURMOUNT-1 Trial (Zepbound, 15 mg) | Duration: 72 weeks | Individual results vary.
Important: Results shown are from clinical trials and represent averages. Individual results vary significantly based on dose, diet, exercise, metabolic health, and adherence. This page is for informational purposes only. Consult a qualified healthcare professional before use.
Tirzepatide (sometimes searched as tricep tide) uses a dose-escalation schedule. Doses increase gradually over the first 20 weeks. This approach reduces side effects. It also allows the body to adjust to the medication. The timeline below shows average outcomes at each phase, drawn from the tirzepatide clinical trial program (SURMOUNT-1 through SURMOUNT-5). Tirzepatide also improves high blood sugar control in patients with type 2 diabetes. For a direct comparison with semaglutide, see the Semaglutide vs Tirzepatide comparison. For the three-way comparison, see Semaglutide vs Tirzepatide vs Retatrutide.
Starting dose: 2.5 mg/week. Appetite suppression begins within the first week. Weight loss during this phase is typically 1–4 lbs. GI side effects are most prominent during this initial phase.
Dose increases from 2.5 mg to 5 mg/week. Average weight loss of 5–7% of body weight by week 12 in clinical trials. Appetite suppression becomes more pronounced. GI side effects typically begin to improve.
Dose escalation continues (5 mg → 10 mg → 15 mg). Most users experience the fastest rate of weight loss during this phase. Average cumulative loss of 14–16% of body weight by week 28.
Maintenance dose of 10–15 mg/week reached. Weight loss continues at a steady rate. Average cumulative loss of 18–20% by week 52. Significant improvements in metabolic markers (blood glucose, lipids, blood pressure).
Average total loss of 20.9–22.5% at week 72 in the SURMOUNT-1 trial (dose-dependent). Visceral fat reduction is particularly pronounced. Maintaining the dose is required to sustain results.
Not everyone achieves the same results. Several factors influence how much weight you lose on tirzepatide. Understanding these factors helps set realistic expectations.
The 15 mg dose produces significantly more weight loss than the 5 mg or 10 mg doses. Tolerating dose escalation is key to maximizing results.
SURMOUNT-1 included dietary counseling. Users who maintain a reduced-calorie diet achieve better outcomes.
Resistance exercise helps preserve lean muscle mass. Tirzepatide produces greater fat loss relative to lean mass compared to semaglutide.
Patients with type 2 diabetes lose slightly less weight than non-diabetic patients, but still achieve clinically significant results.
Consistent weekly dosing and completing the full dose escalation schedule are critical for maximum results.
Clinical trials show an average weight loss of 22.5% of body weight over 72 weeks with tirzepatide 15 mg (Zepbound/SURMOUNT-1). This is the largest weight loss ever recorded in a clinical trial for an approved obesity medication.
Most users notice appetite suppression within the first 1–2 weeks. Measurable weight loss (5–7%) typically occurs within 8–12 weeks. Maximum results are typically achieved at 52–72 weeks.
Yes. The SURMOUNT-5 head-to-head trial showed tirzepatide produced approximately 47% more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
Like semaglutide, most patients regain significant weight after stopping tirzepatide. The SURMOUNT-4 trial showed patients regained approximately 14% of body weight in the year after stopping.
Tirzepatide appears to produce a higher proportion of fat loss relative to lean mass compared to semaglutide, possibly due to its glucagon receptor agonism. Resistance exercise further helps preserve muscle.
Tirzepatide carries a black-box warning for thyroid cancer risk. This is based on thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. As a dual GLP-1 receptor agonist and GIP receptor agonist, it also lowers blood sugar levels. This can cause hypoglycemia when combined with insulin or sulfonylureas. Separately, tirzepatide has shown significant benefit for obstructive sleep apnea. The SURMOUNT-OSA trial demonstrated a 63% reduction in apnea events at the 15 mg dose.
Purgo Labs provides HPLC-verified, third-party tested Tirzepatide for legitimate research purposes. Every batch includes a certificate of analysis.
Shop Tirzepatide at Purgo Labs